Organon was carved out of Merck in 2021 with a specific promise: take a portfolio of mature medicines, add a women’s health focus, and grow steadily without the gamble of early-stage drug discovery. For three years, that held together well enough. Then 2025 arrived, and the earnings number collapsed, even as the sales line barely moved. A business can generate billions in revenue and still report a razor-thin net margin. That is the contradiction sitting at the center of this filing.
The short version
Organon’s revenue has been roughly flat for five years, but its profit margin fell from 16% in 2023 to 3% in 2025, almost entirely because of one-time accounting charges rather than a crumbling business. The stock has nearly doubled over the past six months, yet it trades at a price-to-sales ratio below its own historical median, meaning the market is paying less per dollar of revenue than it usually does. The open question is whether the charges are truly behind it, or whether the SEC investigation and pending acquisition by Sun Pharma rewrite the story before the math can reassert itself.
What the quarter changed
The 10-Q for the quarter ended June 30, 2026 lands in the middle of a company in transition on almost every front at once. The pipeline got busier: the FDA granted expanded approval for TOFIDENCE on June 10, 2026, adding Cytokine Release Syndrome and Pediatric COVID-19 to its label, according to Organon’s press releases. MIUDELLA, a hormone-free copper IUD licensed from Sebela Pharmaceuticals in February 2026, opened its required safety-monitoring program in August and is expected on shelves by late 2026. Neither is a blockbuster yet, but both widen the women’s health shelf that is supposed to be Organon’s long-term identity.
The bigger portfolio news came earlier in the year. In January 2026, the FDA extended NEXPLANON’s approved duration from three years to five, according to Organon’s announcement. That matters because Nexplanon is the company’s single most important women’s health product. A five-year implant means fewer reinsertion procedures, which actually suppresses near-term unit sales, but it also makes the product more attractive to patients and clinicians over time. Organon said it expects Nexplanon sales to stabilize in the second half of 2026 as new-label adoptions offset that reinsertion drag.
One product left the portfolio: Organon divested the Jada postpartum hemorrhage system in January 2026 for up to $465 million, including $440 million in cash, per Q1 2026 results. That is a meaningful cash inflow for a company carrying substantial debt, even if it shrinks the pipeline slightly.
The number that needs explaining
The 10-K for fiscal year 2025 shows net margin at 3%, down from 16% two years earlier. Revenue held nearly flat across those same years, so the top line did not fall; the bottom line did. The culprit, per the filing, is largely $271 million in in-process R&D charges, accounting write-downs taken when licensing deals are struck, not cash leaving the building in most cases. Strip those out and the underlying R&D spend was a fraction of that figure, consistent with Organon’s model of buying and distributing rather than inventing.
Our data show the trailing price-to-earnings ratio looks expensive until you understand it is an artifact of a collapsed denominator, a near-zero earnings year inflating the multiple the way a single bad month inflates a batting average. The price-to-sales ratio, which is harder to distort, sits at 0.6 times, below the company’s own historical median of 0.7 times. The math says the market is paying less per dollar of Organon’s revenue today than it typically has, even after a stock that has nearly doubled in six months.
The cloud that does not lift quietly
The Q1 2026 filing disclosed that the SEC opened its own investigation into what Organon calls the “Nexplanon matter.” An internal review, completed in late 2025, found that wholesalers were encouraged to buy more Nexplanon than they needed at the close of several quarters between 2022 and 2025, helping the company meet guidance. The affected sales were less than 1% of consolidated revenue in any single year, per reporting by Bioxconomy, but the practice contributed to hitting external expectations, which is the part regulators care about. Stockholder lawsuits followed, consolidated in March 2026. The Audit Committee also began a separate review of the timing of biosimilar purchases from a supplier in prior years. No findings of wrongdoing have been announced in that second matter.
These are not small footnotes. They introduce legal cost uncertainty and, more importantly, they sit directly on top of the pending acquisition by Sun Pharmaceutical Industries, announced April 26, 2026, at an enterprise value of $11.75 billion, according to Organon’s announcement. Organon shareholders approved the deal on July 23, 2026, per World Pharma Today, with closing expected in early 2027. An unresolved SEC investigation is exactly the kind of condition that can delay or complicate a closing.
For anyone watching this business, the tension is not really about the quarter. It is about whether the 2025 margin collapse was a one-time accounting event that the filed run-rate will recover from, or the beginning of a messier chapter that the Sun Pharma deal either resolves or inherits.
What compounds
Organon’s model is built on compounding small additions: a label extension here, a biosimilar licensing deal there, a new IUD on the shelf. None of it is dramatic. VTAMA cream, which the 10-Q for the quarter ended June 30, 2026 lists among the company’s dermatology assets, showed consistent improvement in atopic dermatitis across age groups, adding another brick to the portfolio. The Canadian launch of PYZCHIVA, a biosimilar version of the immunology drug ustekinumab, adds another. Individually, these moves are modest. Together, they are the strategy.
The filed revenue trend, flat for five years and showing no meaningful decline, tells a story of a business that is not shrinking but is not yet growing meaningfully either. Whether the new label expansions and product additions can bend that line depends on execution that one quarter cannot confirm.
Reading the numbers
- Net margin, FY2025: 3% (filed in the 2025 10-K). This is what’s left of each dollar of sales after every bill is paid. At 3%, a business earning $6 billion keeps about $180 million. Two years earlier the same business kept roughly $1 billion. The difference is almost entirely accounting charges on licensing deals, not a collapse in the underlying operation. Think of it as a homeowner who wrote down the value of a renovation mid-project: the house still stands, the write-down just hit the income statement.
- Price-to-sales ratio: 0.6 times (our data, vs. historical median of 0.7 times). This is the price tag per dollar of annual revenue. At 0.6 times, a buyer of the whole company at today’s price would be paying 60 cents for every dollar Organon earns in sales. The company has historically traded at 70 cents. A household analogy: imagine a small business that usually sells for 70% of its annual revenue; today it is on offer at 60%. That gap is either a discount or a warning, depending on what happens next.
- In-process R&D charges, FY2025: $271 million (filed in the 2025 10-K). These are accounting charges booked when a company licenses a drug that has not yet been approved. No cash necessarily leaves the building at that moment; the charge is a bookkeeping entry. But it hits the income statement hard, which is why a company with $6 billion in revenue can report near-zero profit. Strip this out and the underlying R&D spend was closer to $85 million, about what a mid-size pharmaceutical company spends in a single quarter of conventional research.
For the standing yardsticks on Organon &: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Organon &.
Sources
- Organon 10-Q, quarter ended June 30, 2026
- Organon 10-Q, quarter ended March 31, 2026
- Organon 10-K, fiscal year ended December 31, 2025
- Organon press release: Nexplanon five-year label extension
- Organon Q1 2026 results
- Organon press release: Sun Pharma acquisition agreement
- World Pharma Today: Sun Pharma buyout
- Bioxconomy: Nexplanon sales practices investigation
- Organon press releases
